Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa-Reference-Cited by-同舟云学术

Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa

Published:2024-02-27 Issue:3 Volume:3 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Kimball Alexa B.¹,Peeva Elena²,Forman Seth³,Moiin Ali⁴,Khattri Saakshi⁵,Porter Martina L.¹,Mangold Aaron R.⁶,Ghosh Pranab⁷,Banfield Christopher⁷,Oemar Barry⁷

Affiliation:

1. Harvard Medical School and Beth Israel Deaconess Medical Center, Boston

2. Pfizer Inc, Collegeville, PA

3. ForCare Medical Center, Tampa, FL

4. Revival Research Institute, LLC, Southfield, MI

5. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York

6. Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ

7. Pfizer, Inc., Cambridge, MA

Publisher

Massachusetts Medical Society

Reference40 articles.

1. Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage

2. Hidradenitis suppurativa: inside and out;Indian J Dermatol,2018

3. Skin diseases in Bamako (Mali)

4. Prevalence of Hidradenitis Suppurativa

5. Population‐based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence on Hidradenitis Suppurativa as an Autoinflammatory Skin Disease;Journal of Clinical Medicine;2024-09-02

2. Januskinaseinhibitoren für dermatologische Erkrankungen;Die Dermatologie;2024-08-30

3. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition;Journal of Clinical Medicine;2024-05-24

4. Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development;Drug Discovery Today;2024-05